Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker JNJ
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | JNJ Johnson & Johnson | Sale | 13,072 | $284.39 | $3.7M Sale | Form 4 ↗ |
| Sep 2, 2026 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 22,527 | $274.74 | $6.2M Sale | Form 4 ↗ |
| Sep 2, 2026 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 11,070 | $274.74 | $3.0M Sale | Form 4 ↗ |
| Aug 17, 2026 | Jennifer L. Taubert EVP, WWC. Innovative Medicine | JNJ Johnson & Johnson | Sale | 15,000 | $263.36 | $4.0M Sale | Form 4 ↗ |
| Aug 13, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 102,315 | $261.00 | $26.7M Sale | Form 4 ↗ |
| Aug 13, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 20,976 | $262.00 | $5.5M Sale | Form 4 ↗ |
| Aug 6, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | JNJ Johnson & Johnson | Sale | 6,574 | $255.93 | $1.7M Sale | Form 4 ↗ |
| Aug 6, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | JNJ Johnson & Johnson | Sale | 9,344 | $257.76 | $2.4M Sale | Form 4 ↗ |
| Aug 5, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 6,523 | $258.74 | $1.7M Sale | Form 4 ↗ |
| Aug 5, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 41,957 | $258.06 | $10.8M Sale | Form 4 ↗ |
| Jul 20, 2026 | Vanessa Broadhurst EVP, Global Corp Affairs | JNJ Johnson & Johnson | Sale | 23,054 | $251.27 | $5.8M Sale | Form 4 ↗ |
| Jun 11, 2026 | Kathryn E. Wengel EVP, Chief TO and Risk Officer | JNJ Johnson & Johnson | Sale | 10,000 | $241.15 | $2.4M Sale | Form 4 ↗ |
| Feb 27, 2026 | Robert J. Decker VP Corporate Controller | JNJ Johnson & Johnson | Sale | 4,075 | $247.87 | $1.0M Sale | Form 4 ↗ |
| Feb 20, 2026 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 1,322 | $245.66 | $324.8K Sale | Form 4 ↗ |
| Feb 18, 2026 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 8,998 | $244.53 | $2.2M Sale | Form 4 ↗ |
| Feb 18, 2026 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 13,625 | $244.20 | $3.3M Sale | Form 4 ↗ |
| Feb 17, 2026 | James D. Swanson EVP, CIO | JNJ Johnson & Johnson | Sale | 20,521 | $242.70 | $5.0M Sale | Form 4 ↗ |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 24,961 | $242.68 | $6.1M Sale | Form 4 ↗ |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 33,386 | $242.75 | $8.1M Sale | Form 4 ↗ |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 12,066 | $242.87 | $2.9M Sale | Form 4 ↗ |
| Feb 17, 2026 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 19,241 | $242.99 | $4.7M Sale | Form 4 ↗ |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | JNJ Johnson & Johnson | Sale | 2,283 | $243.00 | $554.8K Sale | Form 4 ↗ |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | JNJ Johnson & Johnson | Sale | 29,927 | $243.00 | $7.3M Sale | Form 4 ↗ |
| Feb 17, 2026 | John C. Reed EVP, Innovative Medicine, R&D | JNJ Johnson & Johnson | Sale | 21,721 | $243.00 | $5.3M Sale | Form 4 ↗ |
| Feb 17, 2026 | Vanessa Broadhurst EVP, Global Corp Affairs | JNJ Johnson & Johnson | Sale | 6,197 | $243.39 | $1.5M Sale | Form 4 ↗ |
| Feb 13, 2026 | James D. Swanson EVP, CIO | JNJ Johnson & Johnson | Sale | 22,191 | $243.71 | $5.4M Sale | Form 4 ↗ |
| Feb 13, 2026 | James D. Swanson EVP, CIO | JNJ Johnson & Johnson | Sale | 19,368 | $243.76 | $4.7M Sale | Form 4 ↗ |
| Jan 26, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 48,782 | $221.48 | $10.8M Sale | Form 4 ↗ |
| Jan 26, 2026 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 51,218 | $220.99 | $11.3M Sale | Form 4 ↗ |
| Nov 26, 2025 | John G. Morikis Director | JNJ Johnson & Johnson | Buy | 1,250 | $206.15 | $257.7K Buy | Form 4 ↗ |
| Oct 17, 2025 | John C. Reed EVP, Innovative Medicine, R&D | JNJ Johnson & Johnson | Sale | 21,721 | $192.71 | $4.2M Sale | Form 4 ↗ |
| Sep 4, 2025 | Jennifer L. Taubert EVP, WWC. Innovative Medicine | JNJ Johnson & Johnson | Sale | 56,471 | $177.81 | $10.0M Sale | Form 4 ↗ |
| Aug 22, 2025 | Joaquin Duato CEO and Chairman of the Board, Director | JNJ Johnson & Johnson | Sale | 125,824 | $179.21 | $22.5M Sale | Form 4 ↗ |
| Aug 15, 2025 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 16,820 | $176.91 | $3.0M Sale | Form 4 ↗ |
| Jul 17, 2025 | John C. Reed EVP, Innovative Medicine, R&D | JNJ Johnson & Johnson | Sale | 19,137 | $163.55 | $3.1M Sale | Form 4 ↗ |
| Feb 25, 2025 | Robert J. Decker VP Corporate Controller | JNJ Johnson & Johnson | Sale | 6,999 | $165.88 | $1.2M Sale | Form 4 ↗ |
| Feb 18, 2025 | Timothy Schmid EVP, WW Chair, MedTech | JNJ Johnson & Johnson | Sale | 403 | $156.15 | $62.9K Sale | Form 4 ↗ |
| Feb 7, 2025 | Joseph J. Wolk Exec VP, CFO | JNJ Johnson & Johnson | Sale | 13,015 | $153.89 | $2.0M Sale | Form 4 ↗ |
| Dec 12, 2024 | Mark A. Weinberger Director | JNJ Johnson & Johnson | Buy | 1,000 | $147.22 | $147.2K Buy | Form 4 ↗ |
| Apr 30, 2024 | Eugene A. Woods Director | JNJ Johnson & Johnson | Buy | 100 | $145.53 | $14.6K Buy | Form 4 ↗ |
40 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances